MedTrace Logo

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

NCT01059617 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2018-08-20

Study results available
· View outcomes & findings →

Summary

This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.

Conditions

Interventions

BIOLOGICAL

GSK Biologicals' FluLaval®

Intramuscular injection

BIOLOGICAL

Placebo (saline)

Intramuscular injection

BIOLOGICAL

GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A

Intramuscular injections

BIOLOGICAL

GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A

Intramuscular injections

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-09
Primary Completion
2011-01-14
Completion
2011-10-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01059617 on ClinicalTrials.gov